Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial

Authors

Institutions

Publication Details

Journal
BMC Medicine
Published
2024-08-26
DOI
https://doi.org/10.1186/s12916-024-03564-z
Citations
2
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.58

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial

Zhiguo Hou, Chuyu Jing, Boer Shan, Huaying Wang et al.
2 citations
BMC Medicine
Endometrial and Cervical Cancer Treatments
0.58
article

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial

Zhiguo Hou, Chuyu Jing, Boer Shan, Huaying Wang, Wenqing Zhu, Huijuan Yang, Jing Lü, Wei Zhang, Haiming Li, Xi Cheng, Yi Zhang, Ting Yang, Wenjuan Tian, Ren Yulan, Tingting Wang
article en
2 citations

Abstract

No abstract available for this paper.
BMC MedicineVol. 22(1)
Shanghai Medical College of Fudan University (CN), Shanghai Jiao Tong University (CN), Renji Hospital (CN), Fudan University Shanghai Cancer Center (CN), Jiangsu Hengrui Medicine (China) (CN)
National Natural Science Foundation of China, Fudan University, Science and Technology Commission of Shanghai Municipality
Good health and well-being
Openalex Percentile: Top 29%
Endometrial and Cervical Cancer Treatments
0.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial — Zhiguo Hou, Chuyu Jing, et al. · BMC Medicine (2024) | TGRS Research Map | TGRS